XML 106 R70.htm IDEA: XBRL DOCUMENT v3.25.0.1

Option Agreements and License Agreements (Details) - USD ($) $ in Millions	11 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Option Agreements and License Agreements [Line Items]
Expenses	$ 42.0
Regulatory Milestones Member [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	$ 10.0
Paruka Warrant Obligation [Member]
Option Agreements and License Agreements [Line Items]
Warrant purchase percentage	1.00%
Paragon [Member] | Clinical Development Milestones [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	$ 12.0
Paragon [Member] | Regulatory Milestones Member [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	$ 10.0
Paragon [Member] | Antibody Products [Member]
Option Agreements and License Agreements [Line Items]
Royalty payable on product sales, description	low single-digit percentage royalty for antibody products
Nomination Of A Development Candidate [Member] | Paragon [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	$ 1.5
ORKA-001 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	12.0
ORKA-002 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	$ 12.0
ORKA-001 [Member]
Option Agreements and License Agreements [Line Items]
Development costs, percentage	50.00%
Research and development expenses	$ 13.5
ORKA-001 [Member] | Paragon [Member]
Option Agreements and License Agreements [Line Items]
Initiation fee	0.8
ORKA-001 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	2.5
ORKA-001 [Member] | Related Party [Member]
Option Agreements and License Agreements [Line Items]
Accounts payable and other current liabilities	2.8
ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid	2.5
ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid	$ 1.5
ORKA-002 [Member] | Paruka Warrant Obligation [Member]
Option Agreements and License Agreements [Line Items]
Warrant purchase percentage	1.00%
ORKA-002 [Member] | Paragon [Member]
Option Agreements and License Agreements [Line Items]
Research and development expenses	$ 7.8
Development costs		$ 3.3
Research initial fees	0.8
ORKA-002 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	2.5
ORKA-002 [Member] | Related Party [Member]
Option Agreements and License Agreements [Line Items]
Accounts payable and other current liabilities	2.7
ORKA-002 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid	$ 1.5

X

- Definition

class of warrant or right to purchase percentage of outstanding diluted stock maximum.

+ References

No definition available.

+ Details

Name:	orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
Namespace Prefix:	orka_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of development costs.

+ References

No definition available.

+ Details

Name:	orka_DevelopmentCostsPercentage
Namespace Prefix:	orka_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The milestone consideration paid amount.

+ References

No definition available.

+ Details

Name:	orka_MilestoneConsiderationPaid
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non-refundable milestone payments.

+ References

No definition available.

+ Details

Name:	orka_NonRefundableMilestonePayments
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represent the amount of development costs.

+ References

No definition available.

+ Details

Name:	orka_OtherDevelopmentCost
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of research initial fees.

+ References

No definition available.

+ Details

Name:	orka_ResearchInitialFee
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Royalty payable on product sales, description.

+ References

No definition available.

+ Details

Name:	orka_RoyaltyPayableOnProductSales
Namespace Prefix:	orka_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableOtherCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=orka_ParagonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: